3D Culture of Circulating Tumor Cells for Evaluating Early Recurrence and Metastasis in Patients with Hepatocellular Carcinoma

Purpose Circulating tumor cells (CTCs) are considered to be a key factor involved in tumor metastasis. However, the isolation and culture of CTCs in vitro remains challenging, and their clinical application for predicting prognosis and survival is still limited. The development of accurate evaluating system for CTCs will benefit for clinical assessment of HCC. Methods Density gradient centrifugation and magnetic separation based on CD45 antibody were used to isolate CTCs. 3D culture was used to maintain and amplify CTCs and HCC cells. Cellular immunofluorescence was used to identify CTCs and spheroids. The cutoff value of CTC spheroid was calculated using X-tile software. The relationship between clinicopathological variables and CTC spheroids in HCC patients is analyzed. In vivo models were used to evaluate tumor growth and metastasis of CTC spheroids. Results Patient-derived CTCs/HCC cells were isolated and expanded to form spheroids using 3D culture. CTC spheroids could be used to predict short-term recurrence of CTCs compared with conventional CTC enumeration. Different cell lines exhibited different formation rates and grew to different sizes. Identification of CTC spheroids revealed that EpCAM and β-catenin were expressed in spheroids derived from HCC cells and in the HCC/CTCs. EpCAM-positive HCC cells exhibited improved spheroid formation in 3D culture and were more tumorigenic and likely to metastasize to the lung in vivo. Abnormal activation of the Wnt/β-catenin signaling pathway was observed in EpCAM positive cells. Conclusion CTC spheroids could predict prognosis of HCC more precisely compared with conventional CTC enumeration. EpCAM may participate in the formation and survival of CTC spheroids which dependent on Wnt/β-catenin signaling pathway.

[1]  Ying Zhu,et al.  Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy , 2020, Molecular Cancer.

[2]  C. Ye,et al.  Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. , 2019, Journal of hepatology.

[3]  M. Omata,et al.  Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review , 2019, International journal of molecular sciences.

[4]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[5]  Nam-Trung Nguyen,et al.  Circulating tumor microemboli: Progress in molecular understanding and enrichment technologies. , 2018, Biotechnology advances.

[6]  G. Wang,et al.  Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma , 2018, Clinical Cancer Research.

[7]  Jacquelyn O. Russell,et al.  Wnt/β-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology. , 2018, Annual review of pathology.

[8]  Lydia Giannitrapani,et al.  Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns , 2017, BioMed research international.

[9]  Lei Chen,et al.  Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells , 2017, Oncotarget.

[10]  Kai Qu,et al.  MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma , 2017, Cell Death & Disease.

[11]  Manal M. Hassan,et al.  Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma , 2016, Oncotarget.

[12]  Mustafa Yilmaz,et al.  Effect of adipocyte-secreted factors on EpCAM+/CD133+ hepatic stem cell population. , 2016, Biochemical and biophysical research communications.

[13]  J. Massagué,et al.  Metastatic colonization by circulating tumour cells , 2016, Nature.

[14]  Minetta C. Liu,et al.  Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma , 2016, Hepatology.

[15]  Lei Chen,et al.  pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma , 2015, Oncotarget.

[16]  G. Gores,et al.  Liver cancer: Approaching a personalized care. , 2015, Journal of hepatology.

[17]  Lei Chen,et al.  Improved method increases sensitivity for circulating hepatocellular carcinoma cells. , 2015, World journal of gastroenterology.

[18]  V. Mazzaferro,et al.  Early Hepatocellular Carcinoma on the Procrustean Bed of Ablation, Resection, and Transplantation , 2014, Seminars in Liver Disease.

[19]  Sridhar Ramaswamy,et al.  Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.

[20]  J. Shrager,et al.  Circulating Tumor Microemboli Diagnostics for Patients with Non–Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Sridhar Ramaswamy,et al.  Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.

[22]  J. Bruix,et al.  Treatment of Hepatocellular Carcinoma , 2014, Digestive Diseases.

[23]  E. Lianidou,et al.  Circulating tumor cells as promising novel biomarkers in solid cancers , 2014, Critical reviews in clinical laboratory sciences.

[24]  C. Lovitt,et al.  Miniaturized three-dimensional cancer model for drug evaluation. , 2013, Assay and drug development technologies.

[25]  Kam M. Hui,et al.  MiR-214 Targets β-Catenin Pathway to Suppress Invasion, Stem-Like Traits and Recurrence of Human Hepatocellular Carcinoma , 2012, PloS one.

[26]  Z. Yin,et al.  Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. , 2012, Seminars in oncology.

[27]  Sridhar Ramaswamy,et al.  RNA sequencing of pancreatic circulating tumour cells implicates WNT signaling in metastasis , 2012, Nature.

[28]  G. Barrière,et al.  Epithelial Mesenchymal Transition: A New Insight into the Detection of Circulating Tumor Cells , 2012, ISRN oncology.

[29]  J. Bruix,et al.  Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.

[30]  Yong‐Nyun Kim,et al.  Anoikis Resistance: An Essential Prerequisite for Tumor Metastasis , 2012, International journal of cell biology.

[31]  Caroline Dive,et al.  Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Ellis,et al.  A novel platform for detection of CK+ and CK- CTCs. , 2011, Cancer discovery.

[33]  D. Planchard,et al.  Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer , 2011, British Journal of Cancer.

[34]  S. Dent,et al.  USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1 , 2011, EMBO reports.

[35]  Yu Zhang,et al.  Isolation of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Using a Novel Cell Separation Strategy , 2011, Clinical Cancer Research.

[36]  Dai Fukumura,et al.  Malignant cells facilitate lung metastasis by bringing their own soil , 2010, Proceedings of the National Academy of Sciences.

[37]  K. Sugamura,et al.  Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines , 2010, Cancer science.

[38]  Larry Norton,et al.  Tumor Self-Seeding by Circulating Cancer Cells , 2009, Cell.

[39]  M. Emmert-Buck,et al.  Identification of EpCAM as a molecular target of prostate cancer stroma. , 2009, The American journal of pathology.

[40]  N. Meropol The significance of circulating tumor cells as prognostic markers for colon cancer. , 2009, Clinical advances in hematology & oncology : H&O.

[41]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[42]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[43]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Liang Tang,et al.  Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. , 2008, Cancer research.

[45]  Curt Balch,et al.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.

[46]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[47]  Jin Woo Kim,et al.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.

[48]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[49]  Danila Coradini,et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.

[50]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[51]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[52]  Y. Hannun,et al.  EpCAM Is Overexpressed in Breast Cancer and Is a Potential Target for Breast Cancer Gene Therapy , 2004, Cancer Research.

[53]  G. Michalopoulos,et al.  Beta-catenin is temporally regulated during normal liver development. , 2004, Gastroenterology.

[54]  P. Ruck,et al.  Ep‐CAM in malignant liver tumours , 2000, The Journal of pathology.

[55]  C. Lim,et al.  Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy. , 2019, Clinical chemistry.

[56]  A. Desmoulière,et al.  Hepatic stellate cells reversibly express alpha-smooth muscle actin during acute hepatic ischemia. , 1997, Transplantation proceedings.